Caveolin-1: A tumor-promoting role in human cancer

International Journal of Radiation Biology

Volumn 84, Issue 3, 2008, Pages 177-189

  Shatz, Maria ^a   Liscovitch, Mordechai ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cancer; Caveolin 1; Cell survival; Multidrug resistance; Prostate cancer; Signal transduction

Indexed keywords

CAVEOLIN 1; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CAVEOLA; CELL MEMBRANE; ENDOCYTOSIS; HUMAN; LIPID TRANSPORT; METASTASIS; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

CAVEOLAE; CAVEOLIN 1; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 40049105221     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000701745293     Document Type: Article

References (118)

1. Ahn M, Kim H, Kim JT, Lee J, Hyun JW, Park JW, Shin T. 2006. Gamma-ray irradiation stimulates the expression of caveolin-1 and GFAP in rat spinal cord: A study of immunoblot and immunohistochemistry. The Journal of Veterinary Science 7(4):309-314.
2. Ando T, Ishiguro H, Kimura M, Mitsui A, Mori Y, Sugito N, Tomoda K, Mori R, Harada K, Katada T, Ogawa R, Fujii Y, Kuwabara Y. 2007. The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncology Reports 18(3):601-609.
3. Annabi B, Lee YT, Martel C, Pilorget A, Bahary JP, Beliveau R. 2003. Radiation induced-tubulogenesis in endothelial cells is antagonized by the antiangiogenic properties of green tea polyphenol (-) epigallocatechin-3- gallate. Cancer Biology and Therapy 2(6):642-649.
4. Aoki T, Nomura R, Fujimoto T. 1999. Tyrosine phosphorylation of caveolin-1 in the endothelium. Experimental Cell Research 253(2):629-636.
5. Ayala GE, Dai H, Tahir SA, Li R, Timme T, Ittmann M, Frolov A, Wheeler TM, Rowley D, Thompson TC. 2006. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Research 66(10):5159-5164.
6. Barresi V, Cerasoli S, Paioli G, Vitarelli E, Giuffre G, Guiducci G, Tuccari G, Barresi G. 2006. Caveolin-1 in meningiomas: expression and clinico-pathological correlations. Acta Neuropathologica (Berl) 112(5):617-626.
7. Belanger MM, Roussel E, Couet J. 2003. Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs 14(4):281-287.
8. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, Sessa WC. 2000. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nature Medicine 6(12):1362-1367.
9. Burgermeister E, Xing X, Rocken C, Juhasz M, Chen J, Hiber M, Mair K, Shatz M, Liscovitch M, Schmid RM, Ebert MP. 2007. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Research 67(18):8519-8526.
10. Campbell L, Gumbleton M, Griffiths DF. 2003. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. British Journal of Cancer 89(10):1909-1913.
11. Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F, Lisanti MP. 2003. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. American Journal of Pathology 162(6): 2029-2039.
12. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. 2005. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. Journal of Cell Science 118(Pt 7):1493-1503.
13. Cho KA, Ryu SJ, Park JS, Jang IS, Ahn JS, Kim KT, Park SC. 2003. Senescent phenotype can be reversed by reduction of caveolin status. Journal of Biological Chemistry 278(30):27789-27795.
14. Cordes N, Frick S, Brunner TB, Pilarsky C, Grutzmann R, Sipos B, Kloppel G, McKenna WG, Bernhard EJ. 2007. Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene 26(48):6851-6862.
15. Dasari A, Bartholomew JN, Volonte D, Galbiati F. 2006. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Research 66(22):10805-10814.
16. Davidson B, Nesland JM, Goldberg I, Kopolovic J, Gotlieb WH, Bryne M, Ben-Baruch G, Berner A, Reich R. 2001. Caveolin-1 expression in advanced-stage ovarian carcinoma - a clinicopathologic study. Gynecologic Oncology 81(2):166-171.
17. Dietzen DJ, Hastings WR, Lublin DM. 1995. Caveolin is palmitoylated on multiple cysteine residues. Palmitoylation is not necessary for localization of caveolin to caveolae. Journal of Biological Chemistry 270(12):6838-6842.
18. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV. 2001. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293(5539):2449-2452.
19. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, Lisanti MP. 1998a. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Letters 428(3):205-211.
20. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG, Lisanti MP. 1998b. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. Journal of Biological Chemistry 273(32):20448-20455.
21. Engelman JA, Zhang XL, Lisanti MP. 1998c. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Letters 436(3):403-410.
22. Fernandez MA, Albor C, Ingelmo-Torres M, Nixon SJ, Ferguson C, Kurzchalia T, Tebar F, Enrich C, Parton RG, Pol A. 2006. Caveolin-1 is essential for liver regeneration. Science 313(5793):1628-1632.
23. Fielding CJ, Fielding PE. 2001. Caveolae and intracellular trafficking of cholesterol. Advanced Drug Delivery Reviews 49(3):251-264.
24. Fine SW, Lisanti MP, Galbiati F, Li M. 2001. Elevated expression of caveolin-1 in adenocarcinoma of the colon. American Journal Clinical of Pathology 115(5):719-724.
25. Fiucci G, Ravid D, Reich R, Liscovitch M. 2002. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21(15):2365-2375.
26. Fong A, Garcia E, Gwynn L, Lisanti MP, Fazzari MJ, Li M. 2003. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. American Journal Clinical of Pathology 120(1):93-100.
27. Galbiati F, Volonte D, Brown AM, Weinstein DE, Ben-Ze'ev A, Pestell RG, Lisanti MP. 2000. Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. Journal of Biological Chemistry 275(30):23368-23377.
28. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP. 1998. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO Journal 17(22):6633-6648.
29. Galbiati F, Volonte D, Liu J, Capozza F, Frank PG, Zhu L, Pestell RG, Lisanti MP. 2001. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Molecular Biology of the Cell 12(8):2229-2244.
30. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, Lisanti MP, Sessa WC. 1997. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. Journal of Biological Chemistry 272(41):25437-25440.
31. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T, Hamaguchi M. 2001. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Research 61(6):2361-2364.
32. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. 2002. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. American Journal of Pathology 161(5):1647-1656.
33. Horiguchi A, Asano T, Asakuma J, Sumitomo M, Hayakawa M. 2004. Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. Journal of Urology 172(2):718-722.
34. Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A, Lisanti MP, Pestell RG. 2000. The cyclin D1 gene is transcriptionally repressed by caveolin-1. Journal of Biological Chemistry 275(28):21203-21209.
35. Hung KF, Lin SC, Liu CJ, Chang CS, Chang KW, Kao SY. 2003. The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. Journal of Oral Pathology and Medicine 32(8):461-467.
36. Hurlstone AF, Reid G, Reeves JR, Fraser J, Strathdee G, Rahilly M, Parkinson EK, Black DM. 1999. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 18(10):1881-1890.
37. Jodoin J, Demeule M, Fenart L, Cecchelli R, Farmer S, Linton KJ, Higgins CF, Beliveau R. 2003. P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. Journal of Neurochemistry 87(4):1010-1023.
38. Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ. 2004. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU International 93(3):291-296.
39. Ju H, Zou R, Venema VJ, Venema RC. 1997. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. Journal of Biological Chemistry 272(30): 18522-18525.
40. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. 2007. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67(6):614-622.
41. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H. 2002. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94(4):929-933.
42. Kato T, Miyamoto M, Kato K, Cho Y, Itoh T, Morikawa T, Okushiba S, Kondo S, Ohbuchi T, Katoh H. 2004. Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. Cancer Letters 214(1):121-128.
43. Kimura A, Mora S, Shigematsu S, Pessin JE, Saltiel AR. 2002. The insulin receptor catalyzes the tyrosine phosphorylation of caveolin-1. Journal of Biological Chemistry 277(33):30153-30158.
44. Kunze E, Von Bonin F, Werner C, Wendt M, Schlott T. 2006. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. International Journal of Molecular Medicine 17(1):3-13.
45. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC. 1996. Accumulation of glucosylceramides in multidrug-resistant cancer cells. Journal of Biological Chemistry 271(32):19530-19536.
46. Lavie Y, Fiucci G, Liscovitch M. 1998. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. Journal of Biological Chemistry 273(49):32380-32383.
47. Lavie Y, Liscovitch M. 2000. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconjugate Journal 17(3-4):253-259.
48. Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP. 2002. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: Caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. American Journal of Pathology 161(4):1357-1369.
49. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, Wilson MT, Campos-Gonzalez R, Bouzahzah B, Pestell RG, Scherer PE, Lisanti MP. 2000. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Molecular Endocrinology 14(11):1750-1775.
50. Li J, Hassan GS, Williams TM, Minetti C, Pestell RG, Tanowitz HB, Frank PG, Sotgia F, Lisanti MP. 2005. Loss of caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation. Cell Cycle 4(12):1817-1825.
51. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. 2003. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Molecular Cell Biology 23(24):9389-9404.
52. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC. 2001a. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Research 61(11):4386-4392.
53. Li S, Seitz R, Lisanti MP. 1996. Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. Journal of Biological Chemistry 271(7):3863-3868.
54. Li T, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG, Sparano JA, Lisanti MP. 2006. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. American Journal of Pathology 168(6):1998-2013.
55. Li WP, Liu P, Pilcher BK, Anderson RG. 2001b. Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. Journal of Cell Science 114(Pt 7):1397-1408.
56. Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, Tu YH, Cook RF, Sargiacomo M. 1994. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. Journal of Cell Biology 126(1):111-126.
57. Liscovitch M, Burgermeister E, Jain N, Ravid D, Shatz M, Tencer L. 2005. Caveolin and cancer: A complex relationship. In: Mattson MP, editor. Membrane microdomain signaling: Lipid rafts in biology and medicine. Totowa, New Jersey: Humana Press. pp 161-190.
58. Liu P, Li WP, Machleidt T, Anderson RG. 1999. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nature Cell Biology 1(6):369-375.
59. Liu P, Rudick M, Anderson RG. 2002. Multiple functions of caveolin-1. Journal of Biological Chemistry 277(44):41295-41298.
60. Loza-Coll MA, Perera S, Shi W, Filmus J. 2005. A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells. Oncogene 24(10):1727-1737.
61. Maggi D, Biedi C, Segat D, Barbero D, Panetta D, Cordera R. 2002. IGF-I induces caveolin 1 tyrosine phosphorylation and translocation in the lipid rafts. Biochemical and Biophysical Research Communications 295(5):1085-1089.
62. McLaughlin N, Annabi B, Bouzeghrane M, Temme A, Bahary JP, Moumdjian R, Beliveau R. 2006. The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate. Brain Research 1071(1):1-9.
63. Mettouchi A, Klein S, Guo W, Lopez-Lago M, Lemichez E, Westwick JK, Giancotti FG. 2001. Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle. Molecular Cell 8(1):115-127.
64. Montesano R, Roth J, Robert A, Orci L. 1982. Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins. Nature 296(5858):651-653.
65. Moon KC, Lee GK, Yoo SH, Jeon YK, Chung JH, Han J, Chung DH. 2005. Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Research 25(6C):4631-4637.
66. Nabi IR, Le PU. 2003. Caveolae/raft-dependent endocytosis. Journal of Cell Biology 161(4):673-677.
67. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC. 1998. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nature Medicine 4(9):1062-1064.
68. Pang A, Au WY, Kwong YL. 2004. Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. Leukemia Research 28(9):973-977.
69. Park DS, Lee H, Frank PG, Razani B, Nguyen AV, Parlow AF, Russell RG, Hulit J, Pestell RG, Lisanti MP. 2002. Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Molecular Biology of the Cell 13(10):3416-3430.
70. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK. 2001. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 58(5):811-814.
71. Ravid D, Maor S, Werner H, Liscovitch M. 2005. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 24(8):1338-1347.
72. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP. 2001a. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. Journal of Biological Chemistry 276(41):38121-38138.
73. Razani B, Schlegel A, Liu J, Lisanti MP. 2001b. Caveolin-1, a putative tumour suppressor gene. Biochemical Society Transactions 29(Pt 4):494-499.
74. Razani B, Woodman SE, Lisanti MP. 2002. Caveolae: From cell biology to animal physiology. Pharmacological Reviews 54(3):431-467.
75. Regina A, Jodoin J, Khoueir P, Rolland Y, Berthelet F, Moumdjian R, Fenart L, Cecchelli R, Demeule M, Beliveau R. 2004. Down-regulation of caveolin-1 in glioma vasculature: modulation by radiotherapy. Journal of Neuroscience Research 75(2):291-299.
76. Ronaldson PT, Bendayan M, Gingras D, Piquette-Miller M, Bendayan R. 2004. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. Journal of Neurochemistry 89(3):788-800.
77. Roussel E, Belanger MM, Couet J. 2004. G2/M blockade by paclitaxel induces caveolin-1 expression in A549 lung cancer cells: Caveolin-1 as a marker of cytotoxicity. Anticancer Drugs 15(10):961-967.
78. Ryu SJ, Cho KA, Oh YS, Park SC. 2006. Role of Src-specific phosphorylation site on focal adhesion kinase for senescence-associated apoptosis resistance. Apoptosis 11(3):303-313.
79. Salatino M, Beguelin W, Peters MG, Carnevale R, Proietti CJ, Galigniana MD, Vedoy CG, Schillaci R, Charreau EH, Sogayar MC, Elizalde PV. 2006. Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation. Oncogene 25(59):7723-7739.
80. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, Kononen J. 2000. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Research 60(23):6617-6622.
81. Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, Cordon-Cardo C. 2002. Molecular profiling of bladder cancer using cDNA microarrays: Defining histogenesis and biological phenotypes. Cancer Research 62(23):6973-6980.
82. Sato Y, Sagami I, Shimizu T. 2004. Identification of caveolin-1- interacting sites in neuronal nitric-oxide synthase. Molecular mechanism for inhibition of NO formation. Journal of Biological Chemistry 279(10):8827-8836.
83. Satoh T, Yang G, Egawa S, Addai J, Frolov A, Kuwao S, Timme TL, Baba S, Thompson TC. 2003. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97(5):1225-1233.
84. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CD, Schmitt FC, Ashworth A, Reis-Filho JS. 2007. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clinical Cancer Research 13(1):90-101.
85. Scherer PE, Tang Z, Chun M, Sargiacomo M, Lodish HF, Lisanti MP. 1995. Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe. Journal of Biological Chemistry 270(27):16395-16401.
86. Schlegel A, Arvan P, Lisanti MP. 2001. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. Journal of Biological Chemistry 276(6):4398-4408.
87. Schlegel A, Lisanti MP. 2000. A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediatemembrane binding and oligomer/oligomer interactions in vivo. Journal of Biological Chemistry 275(28):21605-21617.
88. Sedding DG, Hermsen J, Seay U, Eickelberg O, Kummer W, Schwencke C, Strasser RH, Tillmanns H, Braun-Dullaeus RC. 2005. Caveolin-1 facilitates mechanosensitive protein kinase B (Akt) signaling in vitro and in vivo. Circulation Research 96(6):635-642.
89. Shack S, Wang XT, Kokkonen GC, Gorospe M, Longo DL, Holbrook NJ. 2003. Caveolin-induced activation of the phosphatidylinositol 3-kinase/Akt pathway increases arsenite cytotoxicity. Molecular Cell Biology 23(7):2407-2414.
90. Siddiqui SS, Siddiqui ZK, Uddin S, Minshall RD, Malik AB. 2007. p38 MAPK activation coupled to endocytosis is a determinant of endothelial monolayer integrity. American Journal of Physiology Lung Cellular and Molecular Physiology 292(1):L114-124.
91. Sotgia F, Schubert W, Pestell RG, Lisanti MP. 2006. Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling. Cancer Biology and Therapy 5(3):292-297.
92. Sowa G, Pypaert M, Sessa WC. 2001. Distinction between signaling mechanisms in lipid rafts vs. caveolae. Proceedings of the National Academy of Sciences USA 98(24):14072-14077.
93. Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD, Shay JW, Gazdar AF, Minna JD. 2004. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Research 64(12):4277-4285.
94. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S, Katoh H. 2002. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. British Journal of Cancer 87(10):1140-1144.
95. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. 2006. Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery 5(3):219-234.
96. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D. 2006. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clinical Cancer Research 12(16):4872-4875.
97. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, Thompson TC. 2001. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Research 61(10):3882-3885.
98. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR. 2002. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. American Journal of Pathology 160(5):1745-1754.
99. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN, Thompson TC. 2000. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 19(29):3256-3265.
100. Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, Gallego S, Ban J, Kovar H, Notario V. 2006. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Research 66(20):9937-9947.
101. Uittenbogaard A, Ying Y, Smart EJ. 1998. Characterization of a cytosolic heat-shock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. Journal of Biological Chemistry 273(11):6525-6532.
102. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL. 2006. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Research and Treatment 95(3):219-228.
103. Volonte D, Zhang K, Lisanti MP, Galbiati F. 2002. Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Molecular Biology of the Cell 13(7):2502-2517.
104. Wary KK, Mariotti A, Zurzolo C, Giancotti FG. 1998. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 94(5):625-634.
105. Williams TM, Cheung MW, Park DS, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG, Lisanti MP. 2003. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Molecular Biology of the Cell 14(3):1027-1042.
106. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, Pestell RG, Di Vizio D, Loda M, Lisanti MP. 2005. Caveolin-1 Promotes Tumor Progression in an Autochthonous Mouse Model of Prostate Cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. Journal of Biological Chemistry 280(26):25134-25145.
107. Williams TM, Lisanti MP. 2005. Caveolin-1 in oncogenic transformation, cancer, and metastasis. American Journal of Physiology Cell Physiology 288(3):C494-506.
108. Wu D, Foreman TL, Gregory CW, McJilton MA, Wescott GG, Ford OH, Alvey RF, Mohler JL, Terrian DM. 2002. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Research 62(8):2423-2429.
109. Xie Z, Zeng X, Waldman T, Glazer RI. 2003. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and downregulates caveolin-1. Cancer Research 63(17):5370-5375.
110. Yamamoto H, Komekado H, Kikuchi A. 2006. Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Developmental Cell 11(2):213-223.
111. Yang CP, Galbiati F, Volonte D, Horwitz SB, Lisanti MP. 1998a. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Letters 439(3):368-372.
112. Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC. 2000. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clinical Cancer Research 6(9):3430-3433.
113. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. 2005. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 103(6):1186-1194.
114. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. 1998b. Elevated expression of caveolin is associated with prostate and breast cancer. Clinical Cancer Research 4(8):1873-1880.
115. Yang G, Truong LD, Wheeler TM, Thompson TC. 1999. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Research 59(22):5719-5723.
116. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, Lee SD, Choi YL, Kim MK, Chung DH. 2003. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 42(2):195-202.
117. Zuluaga S, Alvarez-Barrientos A, Gutierrez-Uzquiza A, Benito M, Nebreda AR, Porras A. 2007. Negative regulation of Akt activity by p38alpha MAP kinase in cardiomyocytes involves membrane localization of PP2A through interaction with caveolin-1. Cell Signaling 19(1):62-74.
118. Zundel W, Swiersz LM, Giaccia A. 2000. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Molecular Cell Biology 20(5):1507-1514.